En route to personalized prophylaxis.

Predicting a patient9s outcome reliably is perhaps the one of the most challenging aspects of the art of medicine. In this issue of Blood, Ay and colleagues introduce science to this art by validating the Khorana risk score (the first risk assessment model that predicts how likely a cancer patient is to develop symptomatic VTE) and confirming the value of 2 biomarkers, D-dimer and soluble P-selectin (sP-selectin), as predictors of thrombosis.1

[1]  C. Marosi,et al.  Prediction of venous thromboembolism in cancer patients. , 2010, Blood.

[2]  Agnes Y. Y. Lee.  Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. , 2010, Hematology. American Society of Hematology. Education Program.

[3]  O. Wagner,et al.  D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Cimminiello,et al.  D-dimer before chemotherapy might predict venous thromboembolism , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[5]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[6]  Gary H Lyman,et al.  American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Marosi,et al.  High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). , 2007, Blood.

[8]  O. Wagner,et al.  Circulating P-selectin and the risk of recurrent venous thromboembolism , 2007, Thrombosis and Haemostasis.

[9]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[10]  M. Dicato,et al.  Thrombosis in cancer , 2011 .